Suppr超能文献

新型具有利尿/利钠特性的ATP敏感性钾通道阻滞剂[3H]U-37883在肾膜中的受体结合特性研究。

Receptor binding characterization in kidney membrane of [3H]U-37883, a novel ATP-sensitive K+ channel blocker with diuretic/natriuretic properties.

作者信息

Meisheri K, Fosset M, Humphrey S, Lazdunski M

机构信息

Upjohn Laboratories, Kalamazoo, Michigan 49001.

出版信息

Mol Pharmacol. 1995 Jan;47(1):155-63.

PMID:7838124
Abstract

U-37883 (4-morpholinecarboximidine-N-1-adamantyl-N-cyclohexyl), a known blocker of ATP-sensitive K+ (KATP) channels, produces natriuresis/diuresis in vivo by a direct effect on the kidney. In the present study, the binding characteristics of the U-37883 receptor were investigated using pig kidney cortex microsomes. [3H]U-37883 (0.5-5 nM, 50 Ci/mmol) exhibited specific binding, which was reversible, increased linearly with protein concentration (50-500 micrograms/ml), and was destroyed after treatment with proteases. Scatchard plots derived from the competition experiments suggested the presence of a single class of low affinity binding sites, with a Kd of 225 nM and a Bmax of 7.8 pmol/mg of protein. A similar Kd value was derived from complementary studies dealing with association and dissociation kinetics. The binding of [3H]U-37883 was tissue specific, because very little specific binding could be detected in microsomes from rat insulinoma cells (RINm5F) and brain. In contrast, these membranes displayed high affinity specific binding of [3H]glyburide, another KATP channel blocker. Finally, analogs of U-37883 that were found to be active KATP channel blockers in isolated rabbit mesenteric artery and active in vivo as diuretics/natriuretics were also found to be active in displacing specific binding of [3H]U-37883, whereas the inactive analogs (no vascular KATP channel-blocking activity and no in vivo diuresis/natriuresis) were inactive in this binding assay. We suggest that the U-37883 binding site represents a functional receptor that mediates the KATP channel antagonism and natriuresis observed with this class of compounds.

摘要

U - 37883(4 - 吗啉甲脒 - N - 1 - 金刚烷基 - N - 环己基)是一种已知的ATP敏感性钾离子(KATP)通道阻滞剂,它通过对肾脏的直接作用在体内产生利钠/利尿作用。在本研究中,使用猪肾皮质微粒体研究了U - 37883受体的结合特性。[3H]U - 37883(0.5 - 5 nM,50 Ci/mmol)表现出特异性结合,这种结合是可逆的,随蛋白质浓度(50 - 500微克/毫升)呈线性增加,并且在用蛋白酶处理后被破坏。竞争实验得出的Scatchard图表明存在一类单一的低亲和力结合位点,Kd为225 nM,Bmax为7.8 pmol/mg蛋白质。从涉及结合和解离动力学的互补研究中得出了类似的Kd值。[3H]U - 37883的结合具有组织特异性,因为在大鼠胰岛素瘤细胞(RINm5F)和脑的微粒体中几乎检测不到特异性结合。相比之下,这些膜显示出[3H]格列本脲(另一种KATP通道阻滞剂)的高亲和力特异性结合。最后,在离体兔肠系膜动脉中被发现是活性KATP通道阻滞剂且在体内作为利尿剂/利钠剂有活性的U - 37883类似物,在取代[3H]U - 37883的特异性结合方面也有活性,而无活性的类似物(无血管KATP通道阻断活性且无体内利尿/利钠作用)在该结合试验中无活性。我们认为U - 37883结合位点代表一种功能性受体,它介导了这类化合物所观察到的KATP通道拮抗作用和利钠作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验